StockNews.AI
APVO
StockNews.AI
138 days

Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

1. Aptevo Therapeutics offers 1.76M shares at $1.19 each via direct offering. 2. Concurrent private placement includes warrants for 3.53M shares, also priced at $1.19.

2m saved
Insight
Article

FAQ

Why Bullish?

Raising funds through direct offerings can bolster APVO's financial position. Successful capital raises often indicate investor confidence, improving stock prospects.

How important is it?

The article discusses funding measures crucial to APVO's ongoing projects, showcasing potential growth trajectories. This strategic funding will likely influence investor sentiment positively.

Why Short Term?

The immediate market reaction will likely reflect funding optimism. However, long-term impacts hinge on how effectively raised capital is utilized.

Related Companies

CRMDXBITVSTM
SEATTLE, WA / ACCESS Newswire / April 3, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, announced today that it has entered into definitive securities purchase agreements for the purchase and sale of 1,764,710 shares of the Company's common stock in a registered direct offering and warrants to purchase up to 3,529,420 shares of common stock in a concurrent private placement (together with the registered direct offering, the "offering") at a combined purchase price of $1.19 per share and accompanying warrant. The warrants issued pursuant to the concurrent private placement will have an exercise price of $1.19 per share, will be exercisable upon the receipt of shareholder approval following the date of issuance and will expire 5 years from the initial exercise date.

Related News